NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma - Very good response predominantly in patients with intestinal type tumors

International Journal of Cancer

Volumn 137, Issue 3, 2015, Pages 678-685

  Schulz, Christoph ^a   Kullmann, Frank ^b   Kunzmann, Volker ^c   Fuchs, Martin ^d   Geissler, Michael ^e   Vehling Kaiser, Ursula ^f   Stauder, Heribert ^g   Wein, Axel ^h   Al Batran, Salah Eddin ⁱ   Kubin, Thomas ^j   Schäfer, Claus ^k   Stintzing, Sebastian ^a   Giessen, Clemens ^a   Modest, Dominik Paul ^a   Ridwelski, Karsten ^l   Heinemann, Volker ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Kliniken Nordoberpfalz   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d KLINIKUM BOGENHAUSEN   (Germany)

^e Hospital Esslingen   (Germany)

^f Center of Oncology   (Germany)

^g Barmherzige Brüder Hospital   (Germany)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ KRANKENHAUS NORDWEST   (Germany)

^j Klinikum Traunstein   (Germany)

^k Department of Internal Medicine II   (Germany)

^l Hospital Magdeburg   (Germany)

more..

Author keywords

adenocarcinoma of the gastroesophageal junction; gastric cancer; neoadjuvant chemotherapy; pCR; R0 resection rate

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CLINICAL STUDY; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROESOPHAGEAL CANCER; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; HYPERTENSION; INTESTINE TUMOR; ISCHEMIC HEART DISEASE; LEUKOPENIA; LIVER TOXICITY; LOSS OF APPETITE; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY DYSFUNCTION; SEPSIS; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURGICAL MORTALITY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; CANCER GRADING; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; GERMANY; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PERIOPERATIVE PERIOD; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84929514111     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29403     Document Type: Article

References (37)

1. Starling N, Cunningham D,. The role of systemic therapy for localised gastric cancer. Ann Oncol 2006; 17 (Suppl 10): x115-x121.
2. Siewert JR, Bottcher K, Stein HJ, et al., Relevant prognostic factors in gastric cancer: ten-year results of the german gastric cancer study. Ann Surg 1998; 228: 449-61.
3. Carr RM, Lynch JP,. At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here? Gastrointest Cancer Res 2008; 2: 253-5.
4. Moehler M, Lyros O, Gockel I, et al., Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008; 14: 3773-80.
5. Stahl M, Mariette C, Haustermans K, et al., Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): vi51-vi56.
6. Waddell T, Verheij M, Allum W, et al.,; European Society for Medical O, European Society of Surgical O, European Society of R, Oncology. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2014; 40: 584-91.
7. Ge L, Wang HJ, Yin D, et al., Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. World J Gastroenterol 2012; 18: 7384-93.
8. Cunningham D, Allum WH, Stenning SP, et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
9. Ychou M, Boige V, Pignon JP, et al., Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-21.
10. Al-Batran SE, Hartmann JT, Probst S, et al., Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 2008; 26: 1435-42.
11. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al., Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006; 24: 4991-7.
12. Roth AD, Fazio N, Stupp R, et al., Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the swiss group for clinical cancer research. J Clin Oncol 2007; 25: 3217-23.
13. Al-Batran SE, Hartmann JT, Hofheinz R, et al., Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the arbeitsgemeinschaft internistische onkologie. Ann Oncol 2008; 19: 1882-7.
14. Al-Batran SE, Pauligk C, Homann N, et al., The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the arbeitsgemeinschaft internistische onkologie (FLOT65+). Eur J Cancer 2013; 49: 835-42.
15. Siewert JR, Stein HJ,. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-9.
16. Becker K, Mueller JD, Schulmacher C, et al., Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-30.
17. Thuss-Patience PC, Hofheinz RD, Arnold D, et al., Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the arbeitsgemeinschaft internistische onkologie (AIO){dagger}. Ann Oncol 2012; 23: 2827-34.
18. Ferri LE, Ades S, Alcindor T, et al., Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol 2012; 23: 1512-17.
19. Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-33.
20. Allum WH, Stenning SP, Bancewicz J, et al., Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-7.
21. Kelsen DP, Ginsberg R, Pajak TF, et al., Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Eng J Med 1998; 339: 1979-84.
22. Kelsen DP, Winter KA, Gunderson LL, et al., Long-term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25: 3719-25.
23. Rohatgi PR, Mansfield PF, Crane CH, et al., Surgical pathology stage by american joint commission on cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 2006; 107: 1475-82.
24. Persiani R, D'Ugo D, Rausei S, et al., Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol 2005; 89: 227-36. discussion 37-8.
25. Schuhmacher C, Gretschel S, Lordick F, et al., Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-18.
26. Biffi R, Fazio N, Luca F, et al., Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 2010; 16: 868-74.
27. Ott K, Weber WA, Lordick F, et al., Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-8.
28. Lorenzen S, Thuss-Patience P, Al-Batran SE, et al., Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol 2013; 24: 2068-73.
29. Lowy AM, Mansfield PF, Leach SD, et al., Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-8.
30. Starling N, Okines A, Cunningham D, et al., A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer 2009; 100: 1725-30.
31. Homann N, Pauligk C, Luley K, et al., Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer 2012; 130: 1706-13.
32. Ott K, Blank S, Becker K, et al., Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10% residual tumor. Langenbeck's Arch Surg 2013; 398: 239-49.
33. Reim D, Gertler R, Novotny A, et al., Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol 2012; 19: 2108-18.
34. Lorenzen S, Blank S, Lordick F, et al., Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol 2012; 19: 2119-27.
35. Eftang LL, Esbensen Y, Tannaes TM, et al., Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival. BMC Cancer 2013; 13: 586.
36. Lei Z, Tan IB, Das K, et al., Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013; 145: 554-65.
37. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-9.